Back to search results

PROMETHEA Study: Early Detection of Liver Cancer

This study, called PROMETHEA, aims to find better ways to detect hepatocellular carcinoma (HCC), a type of liver cancer, early. Currently, HCC is often found at a late stage, making it harder to treat. Researchers are testing different diagnostic methods, including Small RNA sequencing and Rt-qPCR, to identify specific markers in blood samples that can distinguish HCC from other liver conditions or healthy individuals. The goal is to create a reliable, non-invasive blood test for early HCC detection. You may be able to join if you are an adult aged 18 to 100 years with a confirmed diagnosis of HCC, chronic liver disease without HCC, or if you are a healthy volunteer without known liver disease or cancer. The study is currently unclear on its recruitment status.

Study design
This is an observational study planning to enroll 600 participants. It is not a treatment study, but rather focuses on diagnostic testing.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary outcome, diagnostic performance, is measured at the baseline.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07265271

Project for Multi-Omics-Based Early Detection of Hepatocellular Carcinoma (PROMETHEA Study)

Recruiting
Not specifiedAges 18+Observational
City of Hope Medical Center
~600 participants
Updated 2026-07-01 on ClinicalTrials.gov
What's tested:Small RNA sequenceRt-qPCR

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Diagnostic performance of the integrated multi-omics signature for hepatocellular carcinoma detection
Measured over At the baseline

Conditions

Hepatocellular Carcinoma (HCC)

Explore related trials

Chronic Liver DiseaseHepatocellular CarcinomaRetinal Nonattachment, Nonsyndromic Congenital

NCT07265271

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • City of Hope Medical Center

    Duarte, Californiastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Goel Ajay, PhD
[email protected]
626-218-3452
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adults aged 18 to 100 years.
A histologically confirmed diagnosis of hepatocellular carcinoma.
A clinically diagnosed as chronic liver disease, including chronic hepatitis or liver cirrhosis, without evidence of hepatocellular carcinoma.
Healthy volunteers without known liver disease or malignancy.
Received standard diagnostic and staging procedures as per local guidelines
Availability of blood or other biospecimens.
Ability to provide written informed consent.

Exclusion

Lack of or inability to provide informed consent
History of other active malignancies within the past 5 years
Previous liver transplantation
Severe systemic infection or inflammatory disease at the time of enrollment
Inadequate sample quality or quantity

What this trial measures

  • Diagnostic performance of the integrated multi-omics signature for hepatocellular carcinoma detectionAt the baseline

    To evaluate the diagnostic accuracy of the model for distinguishing patients with hepatocellular carcinoma from chronic liver disease and healthy controls, as assessed by the area under the operating characteristic curve (AUC), sensitivity, and specificity.